A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis

NCT06602219 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

222

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis

Interventions

DRUG: LY4100511
DRUG: Placebo

Sponsor

DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company